The present invention is related to novel compounds of the general formula (A), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors, which are useful in the treatment or prevention of diseases particularly Type II diabetes, other complications related to diabetes and other pathogenic conditions in which DPP IV enzyme is involved
Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia that is predominantly caused by in...
Background: Dipeptidyl peptidase-IV (DDP-IV) Inhibitors may represent single anti-diabetic drugs, th...
[[abstract]]A series of (2S)-cyanopyrrolidines with glutamic acid derivatives at the P2 site have be...
The present invention is related to novel compounds of the general formula (A), their tautomeric for...
Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) are of increasing interest to both diabeto...
AIM: To develop novel, potent, selective and orally active inhibitors of Dipeptidyl Peptidase IV wi...
<div><h3>Background</h3><p>There has been great interest in determining whether natural products sho...
[[abstract]]Dipeptidyl peptidase IV (DPP-IV) inhibitors are expected to become a new type of antidia...
BACKGROUND: There has been great interest in determining whether natural products show biological ac...
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a new pharmacological class of drugs for treating Type...
A novel molecular scaffold has been synthesized and its synthesis and incorporation into new analogu...
Dipeptidyl peptidase IV (DPP-4) is a serine protease that plays a crucial role in glucose metabolism...
The aim of this work is to present a simple, practical and efficient protocol for drug design, in pa...
Dipeptidyl peptidase IV (DPP4) is a promising target for the treatment of chronic metabolic type 2 d...
The successful launches of dipeptidyl peptidase IV (DPP IV) inhibitors as oral anti-diabetics warran...
Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia that is predominantly caused by in...
Background: Dipeptidyl peptidase-IV (DDP-IV) Inhibitors may represent single anti-diabetic drugs, th...
[[abstract]]A series of (2S)-cyanopyrrolidines with glutamic acid derivatives at the P2 site have be...
The present invention is related to novel compounds of the general formula (A), their tautomeric for...
Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) are of increasing interest to both diabeto...
AIM: To develop novel, potent, selective and orally active inhibitors of Dipeptidyl Peptidase IV wi...
<div><h3>Background</h3><p>There has been great interest in determining whether natural products sho...
[[abstract]]Dipeptidyl peptidase IV (DPP-IV) inhibitors are expected to become a new type of antidia...
BACKGROUND: There has been great interest in determining whether natural products show biological ac...
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a new pharmacological class of drugs for treating Type...
A novel molecular scaffold has been synthesized and its synthesis and incorporation into new analogu...
Dipeptidyl peptidase IV (DPP-4) is a serine protease that plays a crucial role in glucose metabolism...
The aim of this work is to present a simple, practical and efficient protocol for drug design, in pa...
Dipeptidyl peptidase IV (DPP4) is a promising target for the treatment of chronic metabolic type 2 d...
The successful launches of dipeptidyl peptidase IV (DPP IV) inhibitors as oral anti-diabetics warran...
Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia that is predominantly caused by in...
Background: Dipeptidyl peptidase-IV (DDP-IV) Inhibitors may represent single anti-diabetic drugs, th...
[[abstract]]A series of (2S)-cyanopyrrolidines with glutamic acid derivatives at the P2 site have be...